Tioconazole
Vagistat (tioconazole) is a small molecule pharmaceutical. Tioconazole was first approved as Tz-3 on 1983-02-18. It is used to treat mycoses and vulvovaginal candidiasis in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Vagistat (generic drugs available since 2001-11-21, discontinued: Tz)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tioconazole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VAGISTAT-1 | Combe | N-020676 OTC | 1997-02-11 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tioconazole 1 | ANDA | 2022-05-12 |
| vagistat 3 | ANDA | 2021-02-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| mycoses | — | D009181 | B35-B49 |
| vulvovaginal candidiasis | EFO_0007543 | D002181 | B37.3 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D01: Antifungals for dermatological use
— D01A: Antifungals for topical use
— D01AC: Imidazole and triazole derivatives, topical antifungals
— D01AC07: Tioconazole
G: Genito urinary system and sex hormones
— G01: Gynecological antiinfectives and antiseptics
— G01A: Antiinfectives and antiseptics, excl. combinations with corticosteroids
— G01AF: Imidazole derivatives, gyncological antiinfectives
— G01AF08: Tioconazole
HCPCS
No data
Clinical
Clinical Trials
66 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 3 | 4 | 4 | 6 | 16 |
| Asthma | D001249 | EFO_0000270 | J45 | — | 3 | 5 | 5 | 1 | 13 |
| Pseudohypoparathyroidism | D011547 | E20.1 | — | 4 | — | 1 | — | 5 | |
| Healthy volunteers/patients | — | 2 | — | — | 1 | — | 3 | ||
| Bronchiectasis | D001987 | HP_0002110 | J47 | — | — | — | 2 | — | 2 |
| Post-dural puncture headache | D051299 | — | — | — | 1 | 1 | 2 | ||
| Allergic rhinitis | D065631 | J30.9 | — | 1 | — | 1 | — | 2 | |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | 1 | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Altitude sickness | D000532 | EFO_1000782 | T70.29 | — | 1 | 1 | — | — | 1 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | — | 1 | — | — | 1 |
| Disease progression | D018450 | — | — | 1 | — | — | 1 | ||
| Apnea | D001049 | HP_0002104 | R06.81 | — | 1 | 1 | — | — | 1 |
| Neoplasms | D009369 | C80 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anosmia | D000086582 | — | 2 | — | — | — | 2 | ||
| Olfaction disorders | D000857 | R43.0 | — | 2 | — | — | — | 2 | |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | 1 | — | — | — | 1 | |
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | — | 1 | |
| Ageusia | D000370 | EFO_1001758 | — | 1 | — | — | — | 1 | |
| Virus diseases | D014777 | B34 | — | 1 | — | — | — | 1 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | — | — | — | 1 |
| Leukemia | D007938 | C95 | — | 1 | — | — | — | 1 | |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | 2 | — | — | — | — | 2 | ||
| Non-small-cell lung carcinoma | D002289 | 2 | — | — | — | — | 2 | ||
| Prostatic neoplasms | D011471 | C61 | 1 | — | — | — | — | 1 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | — | — | — | — | 1 |
| Lung neoplasms | D008175 | C34.90 | 1 | — | — | — | — | 1 | |
| Depression | D003863 | F33.9 | 1 | — | — | — | — | 1 | |
| Critical illness | D016638 | 1 | — | — | — | — | 1 | ||
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syncope | D013575 | HP_0001279 | G90.01 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TIOCONAZOLE |
| INN | tioconazole |
| Description | 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole is a member of the class of imidazoles that comprises 2-(2,4-dichlorophenyl)ethylimidazole carrying an additional (2-chloro-3-thienyl)methoxy substituent at position 2. It is an ether, a member of imidazoles, a member of thiophenes and a dichlorobenzene. |
| Classification | Small molecule |
| Drug class | systemic antifungals (miconazole type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Clc1ccc(C(Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1 |
Identifiers
| PDB | — |
| CAS-ID | 65899-73-2 |
| RxCUI | 38298 |
| ChEMBL ID | CHEMBL1200438 |
| ChEBI ID | 77898 |
| PubChem CID | 5482 |
| DrugBank | DB01007 |
| UNII ID | S57Y5X1117 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 438 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,846 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more